EUVIMEDEUVIMED entdecken
KommentarMetaanalyseOpen Access · CC BY 4.0

Commentary: Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis

Hui Liu, Zhe Zhang, Jiabin Xu, Junjie Li

Frontiers in Immunology · 03.08.2026 · 17

DOI: 10.3389/fimmu.2026.1902016 ↗

Kurz gefasst

Kommentar in der Zeitschrift Frontiers in Immunology, online erschienen am 03.08.2026. Verfasst von Hui Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Zibo Central Hospital, Zibo, Shandong, China. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have read with considerable interest the recently published meta-analysis by Le Zhou et al. in Frontiers in Immunology, which pooled available randomized controlled trial (RCT) data to quantify the efficacy and safety profile of immune checkpoint inhibitor (ICI) combined with conventional chemotherapy or chemoradiotherapy for advanced and recurrent cervical carcinoma [1]. This meta-analysis addresses a hot-button clinical question in gynecologic oncology and provides potential reference for individualized immunochemotherapy decision-making for patients with incurable cervical cancer. Nevertheless, three core methodological flaws deviate from the latest formal recommendations laid out in the Cochrane Handbook for Systematic Reviews of Interventions (Version 6.5, November 2024) [2], involving inappropriate statistical model selection, non-compliant publication bias detection with Egger's regression and funnel plots, and suboptimal trial quality assessment relying solely on modified Jadad scale. These methodological drawbacks may bias pooled effect estimates and weaken the robustness of the authors' final clinical conclusions; we hereby elaborate these concerns in detail for the original authors' reconsideration and manuscript revision following authoritative Cochrane methodological standards.Firstly, the authors adopted fixed-effect meta-analysis arbitrarily based on an empirical I² cutoff of less than 50%, which is inconsistent with the pre-specified model-selection principle defined in Cochrane Handbook Chapter 10, Section 10.10.4.1. As explicitly summarized by Higgins et al. [3], the statistical choice between fixed-effect and random-effects pooling models must be finalized a priori in the registered review protocol according to anticipated clinical and methodological heterogeneity across included trials, rather than being modified after observing heterogeneity statistics including I² value or Cochran's Q test results. The fixed-effect model is built on an extremely restrictive mathematical premise that all enrolled RCTs share an identical underlying true treatment effect across the whole study population, an assumption that is clinically reasonable only when all trials adopt fully consistent participant inclusion criteria, identical ICI agents, matched chemotherapy backbones, uniform concurrent radiotherapy protocols and identical disease staging stratification with nearly perfect clinical homogeneity. In the present cervical cancer-focused meta-analysis, the included RCTs recruited multiple distinct ICIs targeting PD-1, PD-L1 or dual-pathway binding sites such as pembrolizumab, durvalumab and cadonilimab; trials enrolled divergent patient cohorts including untreated locally advanced cervical cancer and heavily pretreated recurrent/metastatic disease, while partial studies added pelvic radiotherapy alongside systemic chemotherapy and others applied exclusive systemic combination regimens. Such inherent variation inevitably introduces predictable inter-study clinical heterogeneity from the initial trial design phase. Random-effects model is conceptually mandatory as primary analytical framework regardless of the measured I² inconsistency index, even when observed between-study statistical heterogeneity is numerically low. The authors' practice of switching to fixed-effect pooling for most primary endpoints solely for I²

Schlagwörter

Stichwörter der Autor:innen

meta-analysismethodological commentspublication bias detectionrandom-effects modelrandomized controlled trial

Autor:innen und Institutionen

  • Department of Obstetrics, Zibo Central Hospital, Zibo, Shandong, China.
  • Department of Gynecology, Zibo Central Hospital, Zibo, Shandong, China.
  • Department of Anesthesiology, Zibo Central Hospital, Zibo, Shandong, China.

Zitieren

APA

Liu, H., Zhang, Z., Xu, J., & Li, J. (2026). Commentary: Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1902016

Vancouver

Liu H, Zhang Z, Xu J, Li J. Commentary: Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1902016

BibTeX
@article{Liu2026,
  author = {Liu, Hui and Zhang, Zhe and Xu, Jiabin and Li, Junjie},
  title = {Commentary: Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1902016}
}
Kostenlos starten →